Latest Abagovomab Stories
TSX Venture: QPT EDMONTON, April 6 /PRNewswire-FirstCall/ - Quest PharmaTech Inc.
Therapy targets folate receptors found on cancer cells otherwise resistant to standard chemo ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, is the only hospital in Illinois and Wisconsin to take part in new clinical research involving a treatment designed to target ovarian cancer cells otherwise resistant...
EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S.
CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K.
Oncolytics Biotech has announced positive interim results in its Phase I and Phase II UK combination Reolysin and paclitaxel/carboplatin clinical trials for patients with advanced cancers.
OXiGENE, a biopharmaceutical company, has reported positive interim results from an ongoing Phase II study of Zybrestat in patients with platinum-resistant ovarian cancer.
ImClone Systems has announced that the first patient has been treated in its disease-directed Phase II clinical trial of IMC-1121B in patients with advanced ovarian cancer.
Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research, has started a Phase II clinical trial in the US evaluating the safety and efficacy of its drug candidate, IT-101, in patients with platinum-sensitive ovarian cancer. The study is open for enrollment.
Oncolytics Biotech has initiated patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
- Large; stout; burly.